

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral

MHRA-102232-PIP01-25

Scope of the Application

Active Substance(s)

2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione; Napazimone

Condition(s)

Treatment of primary mitochondrial disease

Pharmaceutical Form(s)

Film-coated tablet, Age-appropriate oral liquid dosage form

Route(s) of Administration

ORAL USE, GASTRIC USE

Name / Corporate name of the PIP applicant

Pharming Technologies B.V.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Pharming Technologies B.V. submitted to the licensing authority on 21/11/2025 21:31 GMT an application for a Paediatric Investigation Plan

The procedure started on 09/12/2025 09:08 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-102232-PIP01-25

Of 05/03/2026 09:35 GMT

On the adopted decision for Napazimone (MHRA-102232-PIP01-25) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for Napazimone, Film-coated tablet, Age-appropriate oral liquid dosage form , ORAL USE, GASTRIC USE .

This decision is addressed to Pharming Technologies B.V., Darwinweg 24, Leiden, NETHERLANDS, 2333 CR

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of primary mitochondrial disease

2.2 Indication(s) targeted by the PIP:

Treatment of primary mitochondrial disease

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablet Age-appropriate oral liquid dosage form

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of film-coated tablets suitable for the paediatric population from 6 years to less than 18 years of age. Study 2 Development of an age-appropriate oral liquid dosage form suitable for children younger than 6 years of age (and paediatric patients unable to swallow the film-coated tablets).
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 3 Single-arm, open-label trial to evaluate the pharmacokinetics, safety and clinical activity of napazimone in paediatric patients from birth to less than 18 years of age with primary mitochondrial disease. Study 4 Randomised, double-blind, placebo-controlled or cross-over trial to evaluate the efficacy, safety and pharmacokinetics and of napazimone in paediatric patients from birth to less than 18 years of age with primary mitochondrial disease.
Extrapolation, Modeling & Simulation Studies	1	Study 5 Use of PopPK analysis to predict initial paediatric doses to be used in the paediatric clinical studies and to subsequently confirm achievement of expected exposure.
Other Studies	1	Study 6 Review of the Mitochondrial Research Patient Cohort database and other literature data (if available) to support the identification and the definition of patient populations with primary mitochondrial disease (PMD) for paediatric interventional

		clinical trial(s) of napazimone (KL1333) and inform potential options for study endpoints.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/03/2034
Deferral of one or more studies contained in the paediatric investigation plan:	Yes